Vitae Focused On Psoriasis After BI Terminates Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Now that its Alzheimer's partnership has ended and a diabetes tie-up is on uncertain ground, the computational drug-design firm has turned primarily to advancing psoriasis candidate VTP-43742.
You may also be interested in...
Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?
Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.
Autoimmune RORγt Program May Portend Change Of Direction For Vitae
The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.